Last updated on December 2016

Phase 3 Study of KHK7580

Brief description of study

This study is designed to evaluate efficacy and safety of KHK7580 orally administered once daily for 32 weeks for patients with secondary hyperparathyroidism receiving peritoneal dialysis. After 32-week treatment period, the subjects will receive KHK7580 in the 20-week extension period to evaluate long-term safety and efficacy.

Clinical Study Identifier: NCT02549417

Contact Investigators or Research Sites near you

Start Over

Kyowa Hakko Kirin

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin
Tokyo, Japan
  Connect »